Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 60 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $20.000 thousand which missed the analyst consensus estimate of $100.000 thousand by 80.00 percent. This is a 88.51 percent decrease over sales of $174.000 thousand the same period last year.